Treatment of PPI-resistant gastro-oesophageal reflux: A systematic review
- PMID: 29935866
- DOI: 10.1016/j.ajg.2018.02.007
Treatment of PPI-resistant gastro-oesophageal reflux: A systematic review
Abstract
Background and study aims: Several studies have demonstrated the superiority of proton-pump inhibitors (PPIs) in resolving erosive gastro-oesophageal reflux disease (GORD). However, this first line of treatment can fail to control symptoms in around 30% of cases, especially in the presence of non-erosive GORD. In situations where the first line of treatment fails, there is a lack of concordance regarding the best strategy to apply. This study presents a systematic review of the trials which have tested second-line treatments after PPI failure.
Methods: The study was conducted according to the PRISMA statement. The systematic review included medical trials written in English which were published between 2000 and 2016 and were retrieved from PubMed and Scopus using the keywords 'PPI-resistant gastro-oesophageal reflux', 'alginate AND gastro-oesophageal reflux', 'hyaluronic acid AND gastro-oesophageal reflux', 'prokinetics AND gastro-oesophageal reflux', 'sucralfate AND gastro-oesophageal reflux' and 'baclofen AND gastro-oesophageal reflux'.
Results: Ten randomised and non-randomised studies were included, which included 1515 patients of both sexes (mean age = 49.19 years, age range = 18-85, males = 700; 46.2%).
Conclusions: A personalised choice of the best treatment for PPI-resistant GORD should be based on the results of an upper endoscopy and pH/MII monitoring. For patients in situations where the first line of treatment fails, we encourage the execution of trials for testing double doses of PPIs against alternative medicaments.
Keywords: Alginate; Baclofen; Endoscopy; GORD; Hyaluronic; NERD; PPI; Prokinetics; pH/MII.
Copyright © 2018 Pan-Arab Association of Gastroenterology. Published by Elsevier B.V. All rights reserved.
Similar articles
-
Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease.Cochrane Database Syst Rev. 2006 Jul 19;(3):CD002095. doi: 10.1002/14651858.CD002095.pub3. Cochrane Database Syst Rev. 2006. Update in: Cochrane Database Syst Rev. 2010 Nov 10;(11):CD002095. doi: 10.1002/14651858.CD002095.pub4. PMID: 16855986 Updated.
-
Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease.Cochrane Database Syst Rev. 2010 Nov 10;(11):CD002095. doi: 10.1002/14651858.CD002095.pub4. Cochrane Database Syst Rev. 2010. Update in: Cochrane Database Syst Rev. 2013 May 31;(5):CD002095. doi: 10.1002/14651858.CD002095.pub5. PMID: 21069670 Updated.
-
Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease.Cochrane Database Syst Rev. 2001;(4):CD002095. doi: 10.1002/14651858.CD002095. Cochrane Database Syst Rev. 2001. Update in: Cochrane Database Syst Rev. 2004 Oct 18;(4):CD002095. doi: 10.1002/14651858.CD002095.pub2. PMID: 11687139 Updated.
-
Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease.Cochrane Database Syst Rev. 2013 May 31;2013(5):CD002095. doi: 10.1002/14651858.CD002095.pub5. Cochrane Database Syst Rev. 2013. PMID: 23728637 Free PMC article.
-
Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease.Cochrane Database Syst Rev. 2000;(2):CD002095. doi: 10.1002/14651858.CD002095. Cochrane Database Syst Rev. 2000. Update in: Cochrane Database Syst Rev. 2001;(4):CD002095. doi: 10.1002/14651858.CD002095. PMID: 10796857 Updated.
Cited by
-
Buccal Buspirone as add-on Therapy to Omeprazole Versus Omeprazole in Treatment of Gastroesophageal Reflux Diseases (GERD).Iran J Pharm Res. 2020 Fall;19(4):113-120. doi: 10.22037/ijpr.2020.113320.14231. Iran J Pharm Res. 2020. PMID: 33841527 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
